|
|
Volumn 143, Issue 1, 2012, Pages 264-265
|
|
A New Era of Hepatitis C Treatment
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ASUNAPREVIR;
BOCEPREVIR;
DACLATASVIR;
PEGINTERFERON ALPHA;
PEGINTERFERON ALPHA2A;
RIBAVIRIN;
SOFOSBUVIR;
TELAPREVIR;
VIRUS RNA;
ANTIVIRAL THERAPY;
CHRONIC HEPATITIS B;
CHRONIC HEPATITIS C;
COST EFFECTIVENESS ANALYSIS;
DIARRHEA;
DRUG COST;
DRUG TOLERABILITY;
FOLLOW UP;
HEALTH CARE QUALITY;
HEPATITIS C VIRUS GENOTYPE 1;
HEPATITIS C VIRUS GENOTYPE 2;
HEPATITIS C VIRUS GENOTYPE 3;
HUMAN;
LIVER CELL;
LIVER TRANSPLANTATION;
NOTE;
PRIORITY JOURNAL;
RETREATMENT;
SUSTAINED VIROLOGIC RESPONSE;
TREATMENT DURATION;
TREATMENT RESPONSE;
|
|
EID: 84881537863
PISSN: 00165085
EISSN: 15280012
Source Type: Journal
DOI: 10.1053/j.gastro.2012.05.025 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|